Cargando…

66. Impact of a Pharmacist-Driven Azithromycin De-escalation Protocol for Community-Acquired Pneumonia

BACKGROUND: Ceftriaxone and azithromycin are common empiric antibiotics for community-acquired pneumonia (CAP). Despite low suspicion for atypical infection, azithromycin is often continued for a full course. Negative laboratory data for atypical bacteria may assist with azithromycin de-escalation....

Descripción completa

Detalles Bibliográficos
Autores principales:	Shakeraneh, Pegah, Steele, Jeffrey, Seabury, Robert, Thomas, Stephen J, Paolino, Kristopher M, Miller, Christopher, Probst, Luke A, Kufel, Wesley D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777273/ http://dx.doi.org/10.1093/ofid/ofaa439.111

Ejemplares similares

769. Comparison of Vancomycin Continuous and Intermittent Infusion Dosing Strategies Among Patients in an Outpatient Antimicrobial Therapy Program
por: Shakeraneh, Pegah, et al.
Publicado: (2019)

1494. Validation of Methicillin-Resistant Staphylococcus aureus (MRSA) Risk Factors in Predicting MRSA Community-Acquired Pneumonia at an Academic Medical Center
por: Arieno, Joelle, et al.
Publicado: (2020)

67. Impact of a Pharmacist-Driven Collaborative Initiative on Staphylococcus aureus Bacteremia Management
por: Kufel, Wesley D, et al.
Publicado: (2020)

187. Vancomycin Plus Ceftaroline Salvage Therapy for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Kufel, Wesley D, et al.
Publicado: (2021)

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations
por: Kufel, Wesley D., et al.
Publicado: (2020)

Appropriate prescribing of azithromycin for community‐acquired pneumonia
por: Qian, Sue, et al.
Publicado: (2022)

135. Designing And Evaluating A Pharmacist-Driven Approach to Outpatient Azithromycin Stewardship
por: Tran, Christina, et al.
Publicado: (2020)

2590. Efficacy of Doxycycline Versus Azithromycin in Community Acquired Pneumonia
por: Mei, Julie, et al.
Publicado: (2023)

Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit
por: Scrimenti, Ali, et al.
Publicado: (2019)

Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis
por: Ito, Akihiro, et al.
Publicado: (2019)

2558. Pharmacy Students’ Perceptions and Confidence to Recommend Appropriate Empiric Antibiotic Therapy in Infective Endocarditis Following Mannequin-Based Simulation
por: Kufel, Wesley D, et al.
Publicado: (2019)

Pharmacist‐driven interventions to de‐escalate urinary antimuscarinics in the Programs of All‐Inclusive Care for the Elderly
por: Ha, Meghan, et al.
Publicado: (2022)

1999. Does Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus PCR Nasal Screening Decrease Time to De-Escalation of MRSA Coverage in Patients with Pneumonia?
por: Waters, Dustin, et al.
Publicado: (2019)

1489. Safety and Performance of a Pharmacist-Driven Nasal MRSA PCR Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia at an Academic Medical Center
por: Meng, Lina, et al.
Publicado: (2020)

1200. Evaluation of Pharmacist-Driven Azithromycin Dose Optimization Protocol for Respiratory Tract Infections as an Antimicrobial Stewardship Initiative
por: Kaur, Satwinder S, et al.
Publicado: (2023)

517. Impact of Doxycycline in Place of Azithromycin for Community-Acquired Pneumonia on Clostridium difficile Infections
por: John, Jamie, et al.
Publicado: (2018)

Lack of pathogen identification influencing antibiotic de-escalation in hospital-acquired pneumonia
por: Bittmann, Matthew C., et al.
Publicado: (2022)

Comparative Effectiveness of β-lactams Vs Azithromycin for Treatment of Outpatient Pediatric Community-acquired Pneumonia
por: Handy, Lori, et al.
Publicado: (2017)

Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia
por: Joung, Mi Kyong, et al.
Publicado: (2011)

Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study
por: Yadegarynia, Davood, et al.
Publicado: (2022)

901. Evaluation of Azithromycin Usage Following a Pharmacist Discontinuation Protocol
por: Percival, Kelly M, et al.
Publicado: (2022)

2603. Acceptance of Pharmacist-Led Stewardship Recommendations for Patients with Community-Acquired Pneumonia
por: Walker, Ramara E, et al.
Publicado: (2023)

Discontinuation Patterns and Cost Avoidance of a Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus Nasal Polymerase Chain Reaction Testing Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia
por: Meng, L, et al.
Publicado: (2021)

1472. Antibiotic De-escalation Compared with Continued Empirical Treatment in Non-Ventilated Hospital-Acquired Pneumonia
por: Alnaimi, Shaikha, et al.
Publicado: (2018)

767. Impact of Standardized Patient Simulation on Pharmacy Students' Confidence and Perceptions in Community-Acquired Bacterial Meningitis Management
por: Kufel, Wesley D, et al.
Publicado: (2023)

Community-acquired infection caused by the uncommon hypervirulent Klebsiella pneumoniae ST66-K2 lineage
por: Rodrigues, Carla, et al.
Publicado: (2020)

Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study
por: Shorr, Andrew F, et al.
Publicado: (2013)

1988. Impact of a Novel Pharmacist Practice Model on Antimicrobial Usage and Hospital-acquired Clostridium difficile (HACDI) Rates
por: Pourgolafshan, Pegah, et al.
Publicado: (2019)

Impact of a Pharmacist-driven Methicillin-resistant Staphylococcus aureus Polymerase Chain Reaction Nasal Swab Protocol on the De-escalation of Empiric Vancomycin in Patients with Pneumonia in a Rural Healthcare Setting
por: Dadzie, Precious, et al.
Publicado: (2019)

2197. Ceftriaxone Monotherapy vs. Ceftriaxone Plus Azithromycin for the Treatment of Community-Acquired Pneumonia in Hospitalized, Non-ICU Patients
por: Murter, Forrest, et al.
Publicado: (2019)

2207. Impact of an Intervention Bundle on Azithromycin Use and 5-Day Durations of Therapy for Ambulatory Pediatric Community Acquired Pneumonia
por: Weber, Matthew J, et al.
Publicado: (2023)

33. Evaluating the Safety and Effectiveness of a Non-Severe Community-Acquired Pneumonia Pharmacist Pathway
por: Sylvain, Kelly, et al.
Publicado: (2021)

Confounding by indication of the safety of de-escalation in community-acquired pneumonia: A simulation study embedded in a prospective cohort
por: van Heijl, Inger, et al.
Publicado: (2019)

Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
por: Han, Rui, et al.
Publicado: (2020)

A retrospective study of azithromycin and ceftizoxime for the management of children with Mycoplasma pneumoniae pneumonia
por: Han, Li-ping, et al.
Publicado: (2021)

42. A Pharmacist-Led Intervention to Decrease Anaerobic Coverage for Hospitalized Patients with Community-Acquired Pneumonia
por: Enzmann, Maxx O, et al.
Publicado: (2020)

Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review
por: Al-Salloum, Jumana, et al.
Publicado: (2021)

Effectiveness of azithromycin in aspiration pneumonia: a prospective observational study
por: Marumo, Satoshi, et al.
Publicado: (2014)

Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma
por: Ho, Derek K-H., et al.
Publicado: (2015)

Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
por: Mori, Nobuaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hgm4acif3g3j3l5r7f9qfkpoc6